Boston Scientific Corp
F:BSX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Boston Scientific Corp
F:BSX
|
US |
|
B
|
Boston Scientific Corp
XMUN:BSX
|
US |
|
H
|
Halma PLC
OTC:HALMY
|
UK |
Intrinsic Value
The intrinsic value of 
Boston Scientific Corp (BSX) under the Base Case is 83.4 EUR per share.
Compared with the current market price of 39.71 EUR, the stock appears
Undervalued by 52% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Boston Scientific Does
Boston Scientific makes medical devices that doctors use to diagnose and treat problems inside the body. Its products include tools for heart care, rhythm management, digestive health, urology, and other minimally invasive procedures. Hospitals, clinics, and specialist doctors buy these devices because they help treat patients without major surgery.
- Headquarters
- United States of America US
- Employees
- 59 000
- IPO date
- May 19, 1992
Boston Scientific has a narrow economic moat
Protected device designs and the time needed to win medical approvals make Boston Scientific’s products difficult to copy. Hospitals also invest in compatible equipment and staff training, making a move to another supplier more work than simply choosing a cheaper device. These barriers protect parts of its business rather than keeping competitors out altogether.
Read the full moat analysis
Revenue & Expenses Breakdown
Boston Scientific Corp
Earnings Waterfall
Boston Scientific Corp
The intrinsic value for Boston Scientific Corp (BSX) under the Base Case is 83.4 EUR.
Compared with the current market price of 39.71 EUR, the stock appears Undervalued by 52% .
